SCAI Expert Consensus Document Addresses Cardio-Oncology Patients Treated in CCLs

January 12, 2016—The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus statement providing cardiologists, oncologists, and internal medicine physicians guidance for treating patients facing concomitant cardiovascular disease and cancer. “SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catheterization Laboratory (CCL)” was released online in Catheterization and Cardiovascular Interventions.

The document is endorsed by the Cardiological Society of India and Sociedad Latino Americana de Cardiologia Intervencionista. The paper aims to increase the competency of cardiovascular professionals providing care to cancer patients.

According to SCAI, advances in cancer therapy have resulted in a steady decline in cancer-related mortality since the 1990s. According to the Centers for Disease Control and Prevention, there are approximately 14.5 million cancer survivors in the United States; in 2020, this number is expected to increase to 20 million. In view of these trends, the need for invasive evaluation and management in the CCL for such patients has increased, stated SCAI.

Cezar A. Iliescu, MD, lead author of the document, commented in SCAI’s announcement, “Little data exists, as cancer patients have been excluded from national percutaneous coronary interventions registries and from most randomized trials involving percutaneous coronary interventions. Therefore, SCAI commissioned a consensus group to define the landscape and provide recommendations based on the available published medical literature and the expertise of operators with accumulated experience in the cardiac catheterization of cancer patients.” Dr. Iliescu is Director of the CCL at MD Anderson Cancer Center in Houston, Texas.

As noted by SCAI, cancer is associated with a hypercoagulable state, which increases the risk of acute thrombotic events. Cancer therapies can cause significant injury to the vasculature, resulting in angina, acute coronary syndromes, arrhythmias, and heart failure, even independently from a direct myocardial effect.

The expert consensus document highlights the review of the mechanisms of vascular toxicities in cancer patients (radiation or chemotherapy induced), and covers several other aspects of cardiovascular care such as screening and cardioprotection, as well as percutaneous coronary interventions in patients with thrombocytopenia and anemia, fractional flow reserve, intravascular ultrasound, and optical coherence tomography for complex intravascular assessment, and deferring stenting, if possible.

The paper also includes noncoronary interventional procedures in cancer patients like endomyocardial biopsy and pericardiocentesis, as well as aortic valvuloplasty and transcatheter aortic valve implantation.

Cardio-oncology is expected to have continued growth in the coming years. Several health care institutions have founded onco-cardiology/cardio-oncology departments, along with fellowship training programs focusing on the cardiology subspecialty, advised SCAI.